Is Geron Stock a Buy Following Its First New Drug Approval?

Shares of Geron (GERN 18.00%) finished the week ended June 7 about 32% higher. The market was reacting to news the company's investors had been waiting to hear for decades. Rytelo is a new treatment for an underserved population. That's generally a recipe for success in the biotechnology industry, but independent companies launching their first commercial product tend to miss expectations. Reasons to buy Geron Corp stock The FDA approved Rytelo for patients with low- to intermediate-risk myelodysplastic syn ...